Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	66.8	47.98	103.78	53.51	18.26
Revenue Growth (YoY)	39.24%	-53.77%	93.95%	193.10%	95.67%
Gross Profit	66.8	47.98	103.78	53.51	18.26
Selling, General & Admin	21.18	23.7	25.55	36.48	41.7
Research & Development	38.47	96.76	51.44	47.59	64.53
Other Operating Expenses	0.85	0.88	5.31	11.63	-
Total Operating Expenses	60.49	121.34	82.3	95.71	106.23
Operating Income	6.31	-73.36	21.48	-42.2	-87.97
Interest Income	2.51	4.74	3.94	1.11	0.35
Interest Expense	-	-	-	-2.61	-1.94
Other Non-Operating Income (Expense)	0.01	0.06	-0.01	-2.72	-0.19
Total Non-Operating Income (Expense)	2.52	4.8	3.92	-4.22	-1.79
Pretax Income	8.83	-68.57	25.4	-46.42	-89.76
Provision for Income Taxes	-0.26	-	-2.6	-	-
Net Income	9.09	-68.57	28	-46.42	-89.76
Net Income to Common	9.09	-68.57	28	-46.42	-89.76
Shares Outstanding (Basic)	56	54	53	38	31
Shares Outstanding (Diluted)	59	54	53	38	31
Shares Change (YoY)	9.25%	1.98%	40.98%	21.65%	38.01%
EPS (Basic)	0.15	-1.27	0.43	-1.23	-2.91
EPS (Diluted)	0.15	-1.27	0.43	-1.23	-2.91
Shares Outstanding	56.41	54.59	53	52.46	38.76
Free Cash Flow	-12.62	-23.44	-33	-7.73	-64.35
Free Cash Flow Per Share	-0.21	-0.43	-0.62	-0.21	-2.08
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	9.45%	-152.91%	20.70%	-78.86%	-481.87%
Profit Margin	13.61%	-142.91%	26.98%	-86.74%	-491.65%
FCF Margin	-18.90%	-48.87%	-31.79%	-14.45%	-352.47%
EBITDA	6.31	-73.36	21.85	-41.33	-87.33
EBITDA Margin	9.45%	-152.91%	21.05%	-77.24%	-478.34%
EBIT	6.31	-73.36	21.48	-42.2	-87.97
EBIT Margin	9.45%	-152.91%	20.70%	-78.86%	-481.87%
Effective Tax Rate	-2.95%	0.00%	-10.23%	0.00%	0.00%

Updated Mar 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q